## Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds

(myeloid differentiation/liquid suspension culture/granulocyte/hemopoiesis)

STEVEN J. COLLINS, FRANCIS W. RUSCETTI, ROBERT E. GALLAGHER, AND ROBERT C. GALLO

\* Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Communicated by Charlotte Friend, February 21, 1978

A human leukemic cell line (designated HL-60) ABSTRACT has recently been established from the peripheral blood leukocytes of a patient with acute promyelocytic leukemia. This cell line displays distinct morphological and histochemical commitment towards myeloid differentiation. The cultured cells are predominantly promyelocytes, but the addition of dimethyl sulfoxide to the culture induces them to differentiate into myelocytes, metamyelocytes, and banded and segmented neutrophils. All 150 clones developed from the HL-60 culture show similar morphological differentiation in the presence of dimethyl sulfoxide. Unlike the morphologically immature promyelocytes, the dimethyl sulfoxide-induced mature cells exhibit functional maturity as exemplified by phagocytic ac-tivity. A number of other compounds previously shown to induce erythroid differentiation of mouse erythroleukemia (Friend) cells can induce analogous maturation of the myeloid HL-60 cells. The marked similarity in behavior of HL-60 cells and Friend cells in the presence of these inducing agents suggests that similar molecular mechanisms are involved in the induction of differentiation of these human myeloid and murine erythroid leukemic cells.

Mouse erythroleukemia (Friend) cells have been extensively studied as a model for mammalian cell differentiation since the description of the erythroid differentiation-inducing effects of dimethyl sulfoxide (Me<sub>2</sub>SO) upon these cells (1). The morphological, biochemical, and immunological changes induced by Me<sub>2</sub>SO in Friend cells have been well characterized (1-3), but the precise mechanism of action of Me<sub>2</sub>SO remains unknown. Similar changes have been induced by compounds other than Me<sub>2</sub>SO, including a variety of low molecular weight, basic, highly polar compounds (4-6) as well as butyric acid (7). The inducing effects of Me<sub>2</sub>SO are not limited to Friend cells but have been demonstrated in other rodent cell lines as well, including morphological and electrophysical changes in a mouse neuroblastoma cell line (8), lysozyme production in certain murine myeloid leukemic cells (9), and erythroid differentiation in a 7.12-dimethylbenz[a]anthracene-induced rat erythroleukemia (10).

We have recently developed a unique human cell line (designated HL-60) from the peripheral blood leukocytes of a patient with acute promyelocytic leukemia. These cultured cells display distinct morphological and histochemical myeloid characteristics (11). Unlike other human leukemic cell lines, which are primarily lymphoblastoid, virtually 100% of the cultured HL-60 cells are stained by myeloid-specific histochemical stains, including chloroacetate esterase, Sudan black, and myeloperoxidase. The majority of cells in this culture are promyelocytes. However, a significant percentage of cells (10–12%) are more mature, having morphological characteristics of myelocytes, metamyelocytes, and banded and segmented neutrophils. Although conditioned medium from a whole human embryo fibroblast strain was apparently required to initiate growth of the HL-60 cells (11), these cells, unlike human myeloid cells in our previous experience (12-14), do not require exogenous factor or conditioned medium for sustained growth. The cells have continuously proliferated and maintained distinct myeloid characteristics for over a year in suspension culture. Their morphological and histochemical myeloid characteristics are similar to those of the patient's uncultured leukemic blood cells, and the modal chromosome number of 44 found in the early passages of the HL-60 culture is the same as the modal chromosome number observed in fresh bone marrow obtained from the patient prior to chemotherapy (11). These findings, together with the ability of the cultured HL-60 cells to be tumorigenic in athymic nude mice (to be published elsewhere), indicate that the HL-60 cells are leukemic in origin.

In the present study we show that after the addition of Me<sub>2</sub>SO and other polar compounds capable of inducing maturation in the above-mentioned rodent cell lines, there is a marked increase in the proportion of mature myeloid cells in the human HL-60 culture. Moreover, these morphologically mature cells, unlike the immature promyelocytes, are now capable of phagocytosis. Thus a differentiation-inducing effect of Me<sub>2</sub>SO and related compounds has now been demonstrated in human cells. The fact that these compounds can induce differentiation in such a variety of different rodent and human cell lines suggests that they may trigger differentiation through common mechanisms in a wide range of mammalian cells.

## MATERIALS AND METHODS

Cells. The HL-60 cells used in these experiments have been maintained in continuous suspension culture for over 1 yr for 48 passages. Cells are cultured in T/30 plastic flasks (Falcon Laboratories, Oxnard, CA) in RPMI-1640 medium (GIBCO, Grand Island, NY) supplemented with 20% heat-inactivated fetal calf serum (Flow Laboratories, Rockville, MD) and gentamicin at 50  $\mu$ g/ml as detailed elsewhere (11). Cell growth was determined by trypan blue dye exclusion. For morphological assessment of the cells, Cytospin slide preparations of 0.2-ml aliquots of cell suspensions were prepared using a Shandon-Elliott Cytospin centrifuge (model SCA-0030, Surrey, England) and stained with Wright-Giemsa. Differential counts were then performed under light microscopy on a minimum of 200 cells for each experimental point.

**Chemicals.** Me<sub>2</sub>SO was diluted from a 15% (vol/vol) stock solution of cryoprotective medium (Microbiological Associates, Bethesda, MD). All other reagents were purchased from Aldrich Chemicals (Milwaukee, WI).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U. S. C. §1734 solely to indicate this fact.

Abbreviations:  $Me_2SO$ , dimethyl sulfoxide; CSF, colony-stimulating factor.

DNA Synthesis. After variable exposure to Me<sub>2</sub>SO, cells were washed free of Me<sub>2</sub>SO and reincubated at a concentration of  $2.5 \times 10^5$  cells per ml for 30 min at 37° in the presence of [<sup>3</sup>H]thymidine (specific activity 0.36 Ci/mmol) at 10  $\mu$ Ci/ml. Five-milliliter cell suspensions were then collected, washed in cold phosphate-buffered saline, and precipitated with 10% trichloroacetic acid. The precipitate was collected on glass Millipore filters and washed with 5% trichloroacetic acid and then with 70% (vol/vol) ethanol. Radioactivity of the precipitate was then determined in Aquasol (New England Nuclear, Boston, MA) in a liquid scintillation counter.

Cloning of HL-60 Cells. HL-60 cells were suspended at concentrations of  $10^4$ – $10^6$  cells per ml in RPMI-1640 medium containing 15% fetal calf serum and 0.8% methylcellulose, and 1 ml of the suspension was incubated in 35-mm petri dishes in a humidified 5% CO<sub>2</sub> environment at 37°. After 7–10 days, visible colonies containing 50–100 cells, presumably arising from a single cell, were individually transferred by sterile pasteur pipette to wells of a Linbro dish (Linbro Chemical Company, New Haven, CT) containing RPMI-1640 medium supplemented with 20% fetal calf serum. As growth continued, cells were transferred to larger wells and ultimately to Falcon T/30 flasks.

**Phagocytosis.** After exposure to various concentrations of Me<sub>2</sub>SO, the cells were washed free of Me<sub>2</sub>SO and resuspended at a concentration of 10<sup>6</sup> cells per ml in RPMI-1640 medium supplemented with 10% fetal calf serum and 10% human AB serum. *Candida albicans*, grown overnight in Sabouraud medium (Difco, Detroit, MI), were washed twice with saline and added to the above HL-60 cell suspension at a final concentration of  $4 \times 10^6$  organisms per ml. The suspension was then incubated for 30 min at 37° and the percent of cells that had phagocytosed the fungi was determined by light microscopy on Wright-Giemsa stained preparations.

## RESULTS

Changes in Morphology of HL-60 Cells Induced by Me<sub>2</sub>SO. The morphological changes induced by Me<sub>2</sub>SO in the HL-60 culture are illustrated in Fig. 1. In the absence of Me<sub>2</sub>SO the HL-60 cells are predominantly typical promyelocytes (Fig. 1 top) with large round nuclei, each containing 2-4 nucleoli and dispersed nuclear chromatin. The cytoplasm is basophilic with prominent azurophilic granules, and the nuclear/cytoplasmic ratio is relatively high. Approximately 10-12% of the uninduced cells are more mature myeloid cells, predominantly myelocytes and metamyelocytes, with rare fully mature segmented neutrophils (Table 1). The addition of appropriate concentrations of Me<sub>2</sub>SO to the culture induces in the majority of cells a striking morphological change characteristic of terminal differentiation of myeloid cells. The induced cells exhibit the following changes: smaller size, decreased nuclear/cytoplasmic ratio, less prominent cytoplasmic granules, marked reduction or complete disappearance of nucleoli, pyknotic changes in nuclear chromatin, and marked indentation, convolution, and segmentation of the nuclei (Fig. 1 middle). Metamyelocytes and neutrophilic bands predominate in the culture 5-7 days after induction rather than segmented neutrophils, the final cells in the myeloid series (Table 1). This pattern is analogous to that seen in induced Friend mouse erythroleukemia cells in which complete erythroid differentiation with extrusion of nuclei and progression to the most mature red blood cells is infrequent even after incubation with the most potent inducing agents (5).

Changes in Cell Growth Kinetics of HL-60 Cells Induced by Me<sub>2</sub>SO. Growth of HL-60 cells begins to plateau at day 5 after treatment with Me<sub>2</sub>SO concentrations of 1.25% and below




FIG. 1. Morphological appearance of uninduced and induced HL-60 cells. Cytospin preparations of suspension cell cultures were stained with Wright-Giemsa before and after treatment with inducing compounds. (*Top*) HL-60 cells cultured without inducer. ( $\times$ 660.) (*Middle*) Cells cultured in 1.25% Me<sub>2</sub>SO for 6 days. ( $\times$ 660.) (*Bottom*) Cells cultured in 60 mM dimethylformamide for 6 days. ( $\times$ 500.)

(Fig. 2). Concentrations of 1.5% or higher completely inhibit cell growth. Maximum differentiation occurs 5–7 days after addition of Me<sub>2</sub>SO (Fig. 3). The concentration of Me<sub>2</sub>SO that gives maximum induction of maturation without inhibition of cell replication is approximately 1.3%. These findings are remarkably similar to those described for Me<sub>2</sub>SO-induced maturation of Friend mouse erythroleukemia cells (1), except that the concentrations of Me<sub>2</sub>SO required for differentiation and inhibition of cell division are slightly lower in the HL-60 system.

The plateaus in the growth curves at 5 days (Fig. 2) suggest

	Myeloid cell type, % of total cells					
Inducer	Myeloblasts	Promyelocytes	Myelocytes	Metamyelocytes	Banded neutrophils	Segmented neutrophils
None	13	76	7	3	1	0
Dimethylformamide (60 mM)	1	14	16	42	17	10
Me <sub>2</sub> SO (1.25%)	· 0	17	17	38	26	2
Butyric acid (0.6 mM)	0	42	44	14	0	0

Table 1. Differential counts of HL-60 cells after incubation with various inducing compounds

HL-60 cells were incubated under standard conditions in the presence of the indicated concentrations of inducing agent. After 6 days, differential counts were performed on Wright–Giemsa stained Cytospin preparations of the cell suspensions.

that the mature cells no longer have the capacity to proliferate. To test directly the capability of these more mature cells to synthesize DNA, [<sup>3</sup>H]thymidine incorporation by HL-60 cells exposed to various concentrations of Me<sub>2</sub>SO was determined. Six days after induction, an inverse relationship was found between the proportion of mature cells in a culture and the capacity for DNA synthesis (Table 2). This is consistent with previous evidence that cells beyond the myelocyte stage of differentiation are no longer capable of further DNA synthesis and cell division (15).

**Phagocytosis by Induced Cells.** Uninduced and induced HL-60 cells after incubation with *Candida albicans* are shown in Fig. 4. After incubation with 1.25% Me<sub>2</sub>SO for 7 days, 85–90% of the cultured cells phagocytose *Candida albicans*, while only 5–10% of the uninduced cells are capable of phagocytosis. Other human hematopoietic cultured cells, including factor-dependent T lymphocytes (16) and blast phase K-562 chronic myeloid leukemic cells (17) exhibit no change in phagocytic capacity when similarly incubated with Me<sub>2</sub>SO. This indicates that the induction of phagocytosis in HL-60 cells is not merely a nonspecific membrane phenomenon generated by Me<sub>2</sub>SO and that functional as well as morphological differentiation has occurred in the myeloid HL-60 cells.

Induction of HL-60 Differentiation by Compounds Other than Me<sub>2</sub>SO. Although Me<sub>2</sub>SO has been the most widely studied inducing compound, numerous other low molecular weight, polar, freely diffusible compounds exist which induce differentiation of Friend mouse erythroleukemia cells at molar concentrations significantly less than that required for Me<sub>2</sub>SO (4-6). We have tested some of these compounds, and all those tested also induce myeloid differentiation of the HL-60 cells (Table 3). The kinetics of induction and extent of morphological differentiation (Fig. 1 bottom) are similar to those described above for Me<sub>2</sub>SO. Although the optimal molar concentrations of the polar inducers in the HL-60 system are 40-60% less than the concentrations used in the Friend mouse cell system (4), the relative potency of the compounds in inducing differentiation is the same in both systems. These striking similarities in the behavior of Friend cells and HL-60 cells in the presence of these compounds suggest that similar mechanisms may be involved in the terminal differentiation of both.

Butyric acid, a potent inducer of differentiation in Friend cells (7) also induces differentiation of the myeloid HL-60 cells at an optimal concentration of 0.6 mM, a concentration con-




FIG. 2. Growth of HL-60 cells in various concentrations of Me<sub>2</sub>SO. Cells were seeded at a concentration of  $2.5 \times 10^5$  cells per ml on day 0 and incubated under standard conditions in the indicated concentrations of Me<sub>2</sub>SO. On the days noted, cells were counted in a hemocytometer chamber. Viability was determined by trypan blue dye exclusions.




FIG. 3. Differentiation induced in HL-60 cells by various concentrations of Me<sub>2</sub>SO. Cells were seeded at a concentration of  $2.5 \times 10^5$  cells per ml on day 0 and incubated under standard conditions in the indicated concentrations of Me<sub>2</sub>SO. At the intervals noted, differential counts were performed on Wright–Giemsa stained Cytospin preparations of 0.2-ml aliquots of the cell suspensions. "Mature myeloid cells" refers to myelocytes, metamyelocytes, and banded and segmented neutrophils.

Table 2. Effect of Me<sub>2</sub>SO induction on DNA synthesis of HL-60 cells

Me <sub>2</sub> SO concentration, %	Mature myeloid cells,* %	[ <sup>3</sup> H]Thymidine incorporation, cpm/10 <sup>6</sup> viable cells
0	13	7258
1.00	58	3983
1.15	73	1609
1.30	94	714

Cells were incubated under standard conditions with the indicated concentrations of Me<sub>2</sub>SO. After 6 days of incubation, cells were washed free of Me<sub>2</sub>SO and [<sup>3</sup>H]thymidine incorporation into trichloroacetic acid-precipitable material was determined.

\* Myelocytes, metamyelocytes, and banded and segmented neutrophils on Wright-Giemsa-stained Cytospin preparations of cell suspensions after 6 days of incubation with Me<sub>2</sub>SO.

siderably less than that required for the above polar compounds. The extent of morphological differentiation with butyric acid is more limited with myelocytes predominating in the induced HL-60 culture (Table 1). Isobutyric acid failed to induce differentiation of HL-60 cells, as has also been noted with Friend cells (7).

**Response of Clones of HL-60 Cells to Me<sub>2</sub>SO.** We have developed 150 clones of HL-60 cells using the cloning technique in semi-solid medium as described in *Materials and Methods*. All of these clones manifest a response to Me<sub>2</sub>SO similar to that shown in Figs. 1, 2, and 3, with some clones developing over 98% mature myeloid cells after 5-7 days of incubation with inducer.

## DISCUSSION

The properties of the HL-60 cells before and after induction of maturation with Me<sub>2</sub>SO are summarized in Table 4. All of




FIG. 4. Phagocytosis of *Candida albicans* by uninduced and induced HL-60 cells. HL-60 cells incubated with *Candida albicans* were Wright-Giemsa stained as detailed in the text. (×500.) (*Upper*) Uninduced HL-60 cells incubated with *Candida*. (*Lower*) Induced HL-60 cells incubated with *Candida*.

Table 3. Polar compounds other than Me<sub>2</sub>SO active in inducing terminal differentiation of HL-60 cells

Inducer	Optimal concentration, mM	Mature myeloid cells,* %	
Acetamide	150	71	
<i>N</i> -Methylacetamide	20	68	
N.N-Dimethylacetamide	10	73	
N-Methylformamide	150	81	
N,N-Dimethylformamide	60	84	
Piperidone	37.5	78	
1-Methyl-2-piperidone	4	65	
Triethylene glycol	100	60	

Differential counts were performed on Wright-Giemsa stained Cytospin preparations of HL-60 cells after 6 days of incubation with the indicated concentration of inducer.

\* Myelocytes, metamyelocytes, and banded and segmented neutrophils.

the observed alterations are characteristic of the differentiation of promyelocytes to mature granulocytes. However, additional detailed morphological, ultrastructural, biochemical and functional analyses are required to determine if the HL-60 promyelocytes and their more mature progeny differ from normal myeloid cells.

Because acute myeloid leukemia can be looked upon as a disease primarily involving a block in myeloid differentiation (18) and continues to be the most difficult leukemia to treat (19), therapeutic intervention using compounds capable of removing such a block in differentiation might be suggested by these results. However, several considerations must temper this ap-

Table 4. Characteristics of uninduced and induced HL-60 cells

Characteristic	Uninduced HL-60	Induced HL-60*
Morphological		
Nucleus	Round with dispersed chromatin	Pyknotic
Nucleoli	2–4 per nucleus	Usually absent
Cytoplasm	Deeply basophilic	Pinkish hue
	Prominent granules	Granules less prominent
Nuclear/cyto- plasmic		
ratio	High	Low
Histochemical		
Chloroacetate-		
esterase	>98% positive	>98% positive
Sudan black	>98% positive	>98% positive
Myeloperoxi-		-
dase	>98% positive	>98% positive
Biochemical	-	•
[ <sup>3</sup> H]Thymidine		
incorpo-		
ration <sup>†</sup>	$7258 \text{ cpm}/10^6 \text{ cells}$	$714 \text{ cpm}/10^6 \text{ cells}$
Physiological	•	
Phagocytosis		
(% ca-		
pable) <sup>‡</sup>	<10%	>85%
Growth in	Continuous proliferation	Proliferation
suspension	for >1 year	ceases

 Cells were induced by incubation for 6 days under standard conditions in 1.3% Me<sub>2</sub>SO.

<sup>†</sup> [<sup>3</sup>H]Thymidine incorporation into trichloroacetic acid-precipitable material.

<sup>‡</sup> Capability of phagocytosing Candida albicans.

proach. With the exception of butyric acid, the compounds used in these experiments are organic solvents that undoubtedly would have many toxic effects when used in the concentrations described here. Indeed, initial experiments in mice using Nmethylacetamide to treat Friend erythroleukemia were complicated by the hepatotoxicity of this compound (20). Moreover, both Friend cells and HL-60 cells are unusual among leukemic cells in their clear commitment to differentiate. In most other leukemic cells the putative block in differentiation occurs at an earlier stage, with the commitment to differentiation being less defined, and Me<sub>2</sub>SO may not have a similar inducing effect on these less committed cells. For example, the K-562 cell line, derived from a patient with chronic myelogenous leukemia in blast crisis (17), contains myeloid-specific membrane antigens (21) but exhibits no morphological or histochemical myeloid differentiation and hence represents a cell line with an earlier arrest in myeloid differentiation than the HL-60 cells. We have not been able to induce morphological or histochemical changes in the K-562 cells with the addition of Me<sub>2</sub>SO.

The mechanism of action of Me<sub>2</sub>SO and other polar compounds in inducing terminal differentiation of Friend cells and HL-60 cells remains unknown. Most of the inducing compounds have cryoprotective properties (22). This has led to the suggestion that their primary mechanism of action may involve alteration of cell membranes (23). Others have suggested that these freely diffusible compounds may act directly in the nucleus, somehow altering conformation of DNA-chromatin complexes in such a way as to initiate transcription of genes coding for differentiation (4). The similarity in the behavior of Friend mouse erythroleukemia cells and HL-60 cells in the presence of these compounds suggests that similar fundamental biological mechanisms are involved in inducing differentiation in both systems. Hence, the myeloid HL-60 cells provide another convenient cell system for studying the mechanism of action of these differentiation-inducing compounds. Moreover, the HL-60 culture provides unlimited quantities of human promyelocytes for biochemical and immunological studies as well as a unique system for the study of human myeloid differentiation in liquid suspension.

The ability of both HL-60 and Friend leukemia cells to undergo maturation under appropriate in vitro conditions indicates, that despite karyotypic abnormalities, the genetic information coding for terminal differentiation in these cells is present and capable of being phenotypically expressed. The reason why such genes are not expressed in the leukemic host is presently unknown, but may be related to abnormalities in host differentiation-inducing factors that normally trigger committed stem cells to differentiate, or to abnormal stem cell receptors for such factors (24). Certain mouse myeloid cell lines, derived from mice with myeloid leukemia, undergo normal morphological and functional maturation in oitro when induced by colony-stimulating factor (CSF), the presumed normal inducer of myeloid differentiation (25-27). The absence of such normal gene expression in vivo could be explained by a blockage or alteration of the normal CSF receptors on these leukemic cells in vivo or by defective CSF production by the leukemic host. Alternatively, receptors for normal host differentiation-inducing factors could be defective or absent on certain other leukemic cells. For example, Friend mouse erythroleukemia cells, unlike the above mouse myeloid cells, do not respond in vitro to erythropoietin (28), the presumed normal inducer of erythroid differentiation, suggesting an absent or defective receptor for this molecule on the surface of Friend cells. This could account for the failure of Friend cells to differentiate *in vivo* even in the presence of normal host erythropoietin. Characterizing the response of the HL-60 cells to various sources of CSF may determine whether normal or defective CSF receptors exist on their surfaces.

- Friend, C., Scher, W., Holland, J. G. & Soto, T. (1971) Proc. Natl. Acad. Sci. USA 68, 378–381.
- 2. Ross, J., Ikawa, Y. & Leder, P. (1972) Proc. Natl. Acad. Sci. USA 69, 3620-3623.
- Ikawa, Y., Furasawa, M. & Sugano, H. (1973) Bibl. Haematol. 39, 955-967.
- 4. Tanaka, M., Levy, J., Terada, M., Breslow, R., Rifkind, R. & Marks, P. (1975) Proc. Natl. Acad. Sci. USA 72, 1003-1006.
- Reuben, R., Wife, R., Breslow, R., Rifkind, R. & Marks, P. (1976) Proc. Natl. Acad. Sci. USA 73, 862–866.
- 6. Preisler, H. P. & Lyman, G. (1975) Cell Differ. 4, 179-185.
- 7. Leder, A. & Leder, P. (1975) Cell 5, 319-322.
- Kimhi, Y., Palfrey, C., Spector, I., Barak, Y. & Littauer, U. Z. (1976) Proc. Natl. Acad. Sci. USA 73, 462-466.
- 9. Krystosek, A. & Sachs, L. (1976) Cell 9, 675-684.
- Kluge, N., Ostertag, W., Sugizama, D., Arndt-Jovin, D., Steinheider, G., Furusawa, M. & Dube, S. (1976) Proc. Natl. Acad. Sci. USA 73, 1237-1240.
- 11. Collins, S. J., Gallo, R. C. & Gallagher, R. E. (1977) Nature 270, 347-349.
- Gallagher, R. E., Salahuddin, S., Hall, W. T., McCredie, K. B. & Gallo, R. C. (1975) Proc. Natl. Acad. Sci. USA 72, 4137–4141.
- Gallagher, R. C., Ruscetti, F., Collins, S. J. & Gallo, R. C. (1978) in Advances in Comparative Leukemia Research, eds. Bentvelzen, P., Hilger, S. J. & Yohn, T. S. (Elsevier North-Holland, Amsterdam, Netherlands), pp. 303–306.
- Gallo, R. C., Ruscetti, F. & Gallagher, R. E. (1978) in Cold Spring Harbor Laboratory Symposium on Differentiation of Normal and Neoplastic Hematopoietic Cells, eds. Clarkson, B., Marks, P. A. & Till, J. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), Vol. 5, in press.
- Craddock, C. G. (1972) in *Hematology*, eds. Williams, W. J., Butler, E., Erslev, A. J. & Rundles, R. W. (McGraw-Hill, New York), pp. 593-623.
- Morgan, D. A., Ruscetti, F. W. & Gallo, R. C. (1976) Science 193, 1007–1008.
- 17. Lozzio, C. B. & Lozzio, B. B. (1975) Blood 45, 321-334.
- Gallo, R. C. (1973) in Modern Trends in Human Leukemia, eds. Neth, R., Gallo, R., Spiegelman, S. & Stohlman, F., Jr. (J.F. Lehmanns Verlag, Munich, W. Germany), pp. 227-237.
- 19. Gunz, F. & Vincent, P. (1977) Leuk. Res. 1, 51-67.
- Preisler, H. D. (1976) in Modern Trends in Human Leukemia II, eds. Neth, R., Gallo, R., Mannweiler, K. & Moloney W. C., (J.P. Lehmanns Verlag, Munich, W. Germany), pp. 161–168.
- 21. Drew, S., Terasaki, P., Billing, R., Bergh, Ô., Minowada, J. & Klein, E. (1977) Blood 49, 715-718.
- 22. Preisler, H. D., Christoff, G. & Taylor, R. (1976) Blood 47, 363-368.
- 23. Lyman, G. H., Preisler, H. D. & Papahadjopoulos, D. (1976) Nature 262, 360-363.
- Moore, M. A. S. (1977) in Recent Advances in Cancer Research: Cell Biology, Molecular Biology and Tumor Virology, ed. Gallo, R. C. (CRC, Cleveland, OH), pp. 79–103.
- 25. Ichikawa, Y. (1969) J. Cell. Physiol. 74, 223-234.
- 26. Fibach, E. & Sachs, L. (1975). J. Cell. Physiol. 86, 221-230.
- Azumi, J. I. & Sachs, L. (1977) Proc. Natl. Acad. Sci. USA 74, 253–257.
- Kluge, N., Gaedicke, G., Steinheider, G., Dube, S. & Ostertag, W. (1974) Exp. Cell Res. 88, 257-262.